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A B S T R A C T
Decentralised or ‘redistributed’ manufacturing represents an attractive choice for production of some cell and
gene therapies (CGTs), in particular personalised therapies. Decentralised manufacturing splits production into
various locations or regions and in doing so, imposes organisational changes on the structure of a company. This
confers a signiﬁcant advantage by democratising supply, creating jobs without geographical restriction to the
central hub and allowing a more ﬂexible response to external pressures and demands. This comes with chal-
lenges that need to be addressed including, a reduction in oversight, decision making and control by central
management which can be critical in maintaining quality in healthcare product manufacturing. The unwitting
adoption of poor business strategies at an early stage in development has the potential to undermine the market
success of otherwise promising products. To maximise the probability of realising the beneﬁts that decentralised
manufacturing of CGTs has to oﬀer, it is important to examine alternative operational paradigms to learn from
their successes and to avoid their failures. Whilst no other situation is quite the same as CGTs, some illustrative
examples of established manufacturing paradigms are described. Each of these shares a unique attribute with
CGTs which aids understanding of how decentralised manufacturing might be implemented for CGTs in a similar
manner. In this paper we present a collection of paradigms that can be drawn on in formulating a roadmap to
success for decentralised production of CGTs.
1. Introduction
Despite the potential of cell and gene-based therapies (CGTs), the
promise of such therapies has yet to come to fruition in the light of
limited commercial and clinical success. With over 900 clinical trials
globally for these advanced therapies (Hanna et al., 2016), the outlook
for the CGT sector is improving. The majority of these trials are in early
phases and led primarily by academic research groups, a trend broadly
reﬂected worldwide (Bisson et al., 2015). Eight CGTs have received
European Union Marketing Authorisation detailed in Table 1. Of these,
Zalmoxis® and Holoclar® have only received conditional approval, and
ChondroCelect®, Provenge® Glybera® and MACI®, have all subsequently
lost marketing authorisation due mostly to business operating con-
siderations (Hanna et al., 2016) (EMA, 2016). Despite this, there has
been signiﬁcant progress and globally, over 60 studies in phase III are
poised at near-entry to the marketplace (Hanna et al., 2016).
While for some CGTs the MOA is related with a high degree of
conﬁdence to speciﬁc Critical Quality Attributes it remains the case that
for others the link is based upon the experience in clinical studies and
may need to be reﬁned with further discoveries about the product
performance post-launch. This is further compounded by the diﬃculty
experienced by the industry in manufacturing cost-eﬀective, well-de-
ﬁned CGT products with the required reproducibility in quality.
Addressing these manufacturing challenges is not an issue that can
easily be resolved in isolation. Both the ever-expanding scientiﬁc
knowledge of the biological systems, the method of product distribution
to the end consumer and follow-up patient care must be considered
when developing a manufacturing strategy for CGT products.
Decentralised manufacturing or redistributed manufacturing will be a
production paradigm which will be considered for production of ad-
vanced healthcare therapies, in particular those with a high degree of
personalisation. Fig. 1 provides an overview of how a centralised hub
and spoke or a decentralised hub and node manufacturing solution for
CGTs may operate in the European market.
Centralised manufacturing has been the dominant operational
model for the creation of goods since the industrial revolution.
Increasing centralisation of manufacturing capability has remained the
dominant model for private enterprise because of its impact in terms of
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economy of scale as ﬁrst seen most clearly in the early ‘Fordist’ factories
in the US and elsewhere. Consequently, decentralised manufacturing
represents a radical departure for most existing healthcare supply sys-
tems. Small-scale manufacturing goes against most of the existing
concepts developed over the last two hundred years and shares simi-
larities with the dispersed piece-rate cottage industries of old, addres-
sing local needs in a more agile manner based on local knowledge and
creating jobs and income across a network of supply. Whilst some at-
tributes of a mass-market product can be dictated by, and customised
to, consumer requirements as in a ‘post-Fordist’ model, there remain
fundamental speciﬁcation features that deﬁne the product identity for
the purposes of quality, safety and eﬃcacy which must be retained.
Compliance with these features must be enforced by rigorous standards
and by suitable manufacturing controls. This makes an automated
solution attractive if it permits some degree of personalisation whilst
maintaining quality and ensuring traceability.
These deﬁning attributes that a decentralised CGT manufacturing
model must possess add signiﬁcant complexities. Many of these chal-
lenges have featured in other healthcare sectors and the resulting
paradigms can be used to propose solutions for the challenges that
decentralisation of CGT manufacture will face.
2. Decentralised manufacturing - healthcare paradigms
Due to the unique characteristics that CGT manufacturing presents,
there is no precedent framework on which to model this emerging
healthcare production system. Nevertheless, there exist a number of
healthcare research and treatment paradigms which provide frame-
works with features suitable for such a system. As the CGT landscape
evolves, these paradigms can provide insight into fundamental orga-
nisational structures within which it is possible to identify opportunities
and to identify limits to decentralised manufacturing.
Useful paradigms include the manufacture of radioisotopes for nu-
clear medicine, personally-titrated anti-cancer agents, total parenteral
nutrition (TPN) products and blood and platelet supplies. The essential,
identiﬁable attributes of decentralised manufacturing are: responsive-
ness to evolving requirements, personalisation to patient requirements
as well as aseptic manufacture, shipping and release. These paradigms
are described here as they all, in their various ways, contain certain
attributes that are similar to the unique set of challenges presented by
the decentralised manufacture of CGTs. This manufacture could in-
itially conceivably be within a clinical setting particularly if govern-
ment money is supporting the endeavour, but equally the insights could
inform a future commercial setting.
It is important to note that tissue transplants historically represent a
ﬁeld which has contributed enormously to the CGT ﬁeld over the course
of decades of success. Transplant medicine represents an important
Table 1
CGTs receiving EMEA marketing authorisation.
Product Mechanism of action Status
Glybera® A gene therapy product repairing faulty fat
metabolism
Authorised
ChondroCelect® An autologous cartilage cell therapy which
expands patient biopsies
Withdrawn
Provenge® Treatment for metastatic castration-resistant
prostate cancer
Withdrawn
Holoclar® Treatment for burn induced limbal stem cell
deﬁciency
Conditional
MACI® A cultured chondrocyte product for cartilage
defects
Suspended
Imlygic® A viral treatment for recurrent
melanoma
Authorised
Strimvelis® A gene therapy for a type of severe combined
immunodeﬁciency
Authorised
Zalmoxis® An adjunctive T-cell therapy for use with stem
cell transplants
Conditional
Fig. 1. Hub and spoke vs. hub and node for manufacturing and delivery of CGTs. The centralised model relies upon delivery of ﬁnished product to multiple users from one or more
centralised hubs. This is closer to traditional methods of manufacturing and has drawbacks for CGTs. Decentralised manufacturing is more akin to a hub and node. In this scenario, the
nodes deliver product to their immediate surrounding supported by the hub, but nodes are not fully dependent upon the hub.
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source of knowledge for manufacturing and handling, but these pro-
ducts are in most cases conducted under tissue or transplant regulations
which are unlikely to apply for manufactured CGTs. For this research
we examined products where GMP applies which would be produced
under similar licensure to CGTs.
For the purposes of these paradigm comparisons, the CGTs can be
deﬁned as some allogeneic, but mainly autologous products whose
mode of action depends on living cells or genetic content that are more
than minimally manipulated and that depend for their eﬃcacy on ad-
ministration at a systemic level or to a restricted compartment of the
body or involve tailoring in a personalised, craft-based manner.
2.1. The Total parenteral nutrition paradigm
Total parenteral nutrition (TPN) is the name given to the feeding of
a person intravenously. Despite the connotations of this term, this does
not have to include the whole nutritional spectrum and some in-
dividuals may only need a few supplemented chemicals, minerals or
vitamins. TPN is a highly customised formula which has to be pre-
scribed for the individual patient requirement. In this regard, it is likely
similar to many aspirational CGTs in that the end user receives a truly
customised product for their needs and the product must be sterile or
aseptic. Despite these similarities, the TPN market could be considered
more mature, with a larger number of products in routine use rather
than remaining aspirational goals.
Patients undergoing TPN require assessment by a trained dietitian
and, depending on their needs, may receive a pre-prepared solution, a
few simple constituents or a fully customised formula. This assessment
and preparation is not trivial and the potential consequences of mis-
management can be severe and potentially life-threatening.
Unlike the majority of potential CGT products, the constituents of a
TPN therapy are relatively stable components with long shelf lives. The
TPN paradigm is similar to the potential decentralised model in a
number of critical ways. The constituents are, unlike those involved in
CGT manufacture, largely simple, well-deﬁned and stable, but parallels
exist in their susceptibility to contamination, both with trace elements
(Pluhator-Murton et al., 1999) and, more seriously, infectious agents
(Tresoldi et al., 2000). This vulnerability to contamination has pre-
sented seriously on two notable occasions in the UK. The ‘Devonport
incident’ 40 years ago resulted in the deaths of 5 people due to a failure
in endpoint sterilisation. This was not picked up through routine testing
because samples were not taken from suitable representative locations
of the batch (Meers et al., 1973). A similar incident occurred more
recently with a bacterial contamination by Bacillus cereus in 2014
(Public Health England, 2014). Whilst the impact of the Devonport
incident was evident the impact was minimised as it occurred on a
relatively small scale. In addition, the Devonport incident led to the
development of modern validation techniques aimed at proving that the
manufacturing equipment is functioning as intended and that the per-
sonnel training is up to date and suitable. Sterility assurance in TPNs is
based on the parametric release of autoclaved goods that have been
made to a known ceiling for the allowable bioburden. While CGTs must
be made aseptically it is nevertheless desirable, though not always the
current practice, to make the goods to a control strategy in which the
design space is deﬁned in such a way that the process features that exert
the most inﬂuence over product parameters are known to be controlled
within ranges that will not result in a failed batch to a tolerable level of
conﬁdence. While the 6-log sterility assurance level of an autoclaved
product is a very high level of assurance it is not unreasonable to expect
that, with time and growing understanding of unit operations for CGTs,
we will see six-sigma-level assurance of quality with respect to other
CQAs.
This challenging manufacturing supply chain of TPN is remarkably
similar to that posed by emerging CGTs which require a complex ‘bill of
materials’ including chemicals and solutions, all drawn from certiﬁed
sources. The number of potential constituents of a TPN therapy is large
and their properties varied. Of particular concern, a large number of
these constituents are listed as being in short supply which may have
serious implications for patient health (Mirtallo et al., 2012). Part of
this supply challenge is due to the ‘just-in-time’ inventory practice of
many healthcare providers. This is further compounded by the fact
relatively few manufacturers produce each speciﬁc constituent. If one
supplier is removed either through failure to comply with cGMP man-
ufacturing practices or voluntarily because the corporate strategy
changes, the ramp-up times to change supplier can be long and may
result in a short-term failure in supply. Some healthcare providers
stockpile products which they consider to be at risk of being in short
supply or may switch to another supply chain, neither of which is ideal
(Mirtallo et al., 2012). Modern cost-saving measures are driving down
inventory volumes in hospitals in favour of predictive ordering (Moore,
2016; Romero and Lefebvre, 2015). This commoditised supply chain
enabled by tight procurement procedures combined with frequent ﬁn-
ishing operations in clinic as part of supply represent the key areas this
sector could contribute to eﬃcient management of the emerging CGT
sector.
2.2. The nuclear medicine paradigm
Nuclear medicine involves the use of radioactive materials primarily
for diagnosis and imaging purposes. This paradigm is in many ways
distant from CGTs but shares certain key attributes namely the relative
instability of the product and the requirement for its specialised
handling. In addition to this, it is a particularly relevant paradigm to
decentralised manufacturing of CGTs as it has exceedingly high sunk
costs for manufacturing and emerging manufacturing platforms are
currently being evaluated which may move towards decentralisation.
The principal radioisotope used in medical imaging worldwide is
technetium-99 m (99mTc). This makes up around 80–85% (30 million
procedures) of all diagnostic activity using nuclear medicine globally.
The isotope is derived almost exclusively from uranium-235 in a small
number of research nuclear reactors. The shipped precursor of tech-
netium-99 m is molybdenum which has a half-life of around 66 days,
allowing worldwide shipping. However, for nuclear medicine purposes,
the half-life is much shorter at around 6-h (Amin et al., 2014). For
positron emission tomography (PET) imaging, the transport distances
are much reduced as the isotope-labelled agent, 18F–ﬂuorodeox-
yglucose (the principal radiopharmaceutical for PET imaging), has a
half-life of only 110 min, which limits the eﬀective transport distances
to journeys of around 2 h as a maximum. The short eﬃcacious dura-
tions for these isotopes limit the ﬂexibility in pause steps following
certain processes and ﬁx the temporal relationship between product,
practitioner and patient in a similar manner to CGTs.
These radioisotope examples represent the same dilemma facing the
manufacturer of CGT products. Investment in the manufacturing plat-
form is expensive not only in the form of infrastructure and equipment,
but also in terms of amortising the costs of the strong and active re-
search base that is required to push the manufacturing technology to-
wards innovative platforms. Similarly, shipping and transport is com-
plex due to the requirement for robust and secure containers. This
necessitates online monitoring and tracking systems to ensure that the
products comply with the release criteria once they reach their desti-
nation. Finally, once the radiopharmaceuticals reach the end user, they
have to be reconstituted and/or prepared for use by technically-com-
petent person/s. Current shortages in the supply of radioisotopes are
partly due to a shortage of raw materials, but also to a highly complex
supply chain in which each step is susceptible to inﬂuence by external
stressors. This inherent fragility has led to global shortages in supply.
Current supply of radiopharmaceuticals has evolved from a large
number of research reactors which initially produced 99mTc as a by-
product. As its value increased, production was re-oriented to produce
more 99mTc. The initial investment in labour, research and infra-
structure for these research reactors was extremely high and one that
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has not, for the most part, continued (NEA, 2010). This issue is ex-
acerbated by the fact that 99mTc is not sold for a price which reﬂects the
high sunk capital and research costs which went into the initial in-
vestment cycle.
More recently it has been recognised that full cost recovery (to cover
wear and tear and re-investment of the money spent on production
facilities) is needed to make the supply sustainable. This picture is al-
most a mirror of the tissue engineering, regenerative medicine and CGT
marketplace which currently has few sustained marketplace successes
and a handful of commercial failures. Notable success stories for patient
outcomes tend to be small studies in which the high costs are borne by a
research, clinical trial or medical infrastructure (Cuende et al., 2014;
Hourd et al., 2014) rather than a typical re-imbursement model for an
oﬀ-the-shelf product (Cohen et al., 2006). Whilst this arrangement al-
lows exploratory research studies to progress, it remains a disincentive
to investment in large-scale manufacture. One of the directions that the
UK has decided to pursue for isotope generation is that of distributed
manufacture using cyclotrons (a type of particle accelerator) on a
smaller scale. This is already the case for PET tracers and technical
barriers for producing 99mTc are being addressed in the medium term.
This incremental approach to investment is well-suited to the current
economic climate in which single, large-scale capital investments in
novel plant are diﬃcult to ﬁnance until market success has been de-
monstrated.
The complex ﬁnancial arrangement of nuclear medicine as well as
the recent interest in decentralised production make this paradigm an
interesting proposition for comparison particularly around shared li-
abilities of ﬁnancial responsibility. Additionally, the release at risk
nature of radiopharma combined with the need for rapid QC provide
additional similarities to be considered. Interestingly, there are reg-
ulatory disparities between regions for nuclear medicine which con-
strain manufacturing strategies between regions. This regulatory con-
straint is similar to the CGT landscape.
2.3. The personalised anti-cancer drug paradigm
‘Personalised’, ‘patient-speciﬁc’, ‘targeted’ and ‘stratiﬁed’ are a
number of terms which collectively describe better matching of thera-
pies to the patient needs. This approach describes care in which in-
dividual's unique characteristics and genetic proﬁle guide the clinical
decision-making process. The aim of this process is to increase the
chance of successful treatment through matching the right patient with
the right dose of the right product at the right time. This evidently
shares a number of key similarities to the CGT approach where a highly
personalised product is presented for each patient.
Personalised medicine has evolved rapidly in the last few years as
we begin to gain a better understanding of the complex molecular and
genetic factors which make us unique. These unique characteristics are
not only part of our physical identity, but play a part in our health. As
this understanding has advanced it has become more apparent that
some patients are more easily treatable than others. In no ﬁeld is this
more apparent than the ﬁeld of cancer medicine. The mechanisms in
each case have become clearer more recently(Jackson and Chester,
2015).
The personalised anti-cancer medicine paradigm shares a number of
similarities with the manner in which a CGT may be rolled out.
Personalised medicine has to be based on a deep understanding of the
patient's individual needs. In the medium- to long-term, individuals
may undergo a health screening which includes this information as
standard. Currently the most comprehensive screening is only under-
taken by the wealthy, the curious or those who require it for a medical
investigation following a diagnosis. However, there is signiﬁcant pro-
gress towards both driving the costs of these tests down, as well as
utilising them for a more complete understanding of patient and pro-
duct (Harrison et al., 2017a). This initial screening imposes delays to
treatment while samples are taken, sent for analysis, clinical decision
making occurs and a customised therapeutic option is formulated.
One of the recent evolutions in cancer medicines is the use of ‘dose
banding’. This repackages therapies into diﬀerent doses which are then
distributed to speciﬁc patients. This has helped to reduce wastage of
drugs and monoclonal antibodies by personalising the therapy and by
dictating the degree of personalisation within the framework of the
established banded dosimetry (Mayor, 2016). This approach of func-
tionally-targeted personalisation is an excellent example of a patient-
speciﬁc product which has similar degrees of personalisation, dictated
by eﬃcacy and cost, to the approach that decentralised manufacturing
must undertake. This approach has the potential to progress further as
the screening of patient genetic data becomes more routine. Patients
can be stratiﬁed into populations speciﬁcally to aid in delivering the
correct doses of drugs that have a narrow therapeutic range. In the case
of autologous CGTs from a diseased patient population, it is important
to note that there may be little room for ﬂexibility in formulation and
dosing. Rather the patient may need to be qualiﬁed for treatment by
meeting a threshold decided by a prognostic text or assay prior to
manufacturing.
Combination drug therapies are used to treat diﬃcult cancer cases.
As nano-medicines and theranostics advance further, the therapeutic
options will allow decisions relating to formulation, the preferred me-
chanism of action and the preferred delivery route for each case (Hare
et al., 2016). Already this has strong parallels with the situation for an
autologous regenerative medicine product. In this scenario, patient
material would be taken, processed or expanded and returned to the
patient as a treatment.
Personalised nanomedicines for cancer are also very similar to CGTs
in the way that they are targeted. Prognostics are needed in order to
identify patients that are likely to respond positively in many circum-
stances (O'Brien et al., 2004; Park, 2013; Venditto and Szoka, 2013).
More eﬀective use for future CGTs will, like cancer nanomedicines,
beneﬁt from a move away from administration according to ﬁxed for-
mulations towards personalised posology based upon disease- or pa-
thology-driven research. This will depend on a better understanding of
the underlying mechanisms by which the therapeutic eﬀect occurs and
their relationship to the speciﬁc patient.
2.4. The blood supply chain paradigm
Patients around the world depend on a fresh supply of blood pro-
ducts each day. The entire blood-products supply chain relies on donors
and eﬃcient transport from multiple distributed facilities to sorting
locations and ﬁnally back out to multiple end users. There are over a
hundred diﬀerent products which can be derived from blood, making it
a complex supply chain proposition.
The most important products are red blood cells (63.4%), plasma
(17.8%), platelets (13.6%) and cryoprecipitate (5%) (Whitaker and
Hinkins, 2011). These products are able to be further processed into
irradiated or washed forms or used as raw materials for the manu-
facture of recombinant products.
The decision to donate blood is dependent upon many factors such
as convenience, accessibility, comfort and risk all of which must be
managed in order to establish supply to meet demand. Often there are
periods in which supply becomes more challenging and for this reason
some stockpiling must occur. Supply of blood products also requires
immunological-matching. This means that a range of products must be
held to match the estimated demand. This is a similar situation to that
facing haplobanks of cells which are partially patient-matched thera-
pies cell therapies with an acceptable partial immunological match
between donor and recepient. The overall goal of the blood supply
chain is to ensure that demand is met whilst minimising wastage.
The blood supply chain can be understood in terms of collection,
production, inventory and supply echelons. These are similar to those of
a potentially centralised manufacturing process for CGTs (Fig. 2).
Sourcing of blood and production of blood products is dictated more by
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supply for blood than by selling price as reimbursement for the core
products is relatively plentiful in health services. Conversely CGT
sourcing and production is likely to be driven by commercial oppor-
tunity for speciﬁc at-risk or high-value patient groups. The shelf life of
blood products ranges from 5 days (platelets) to 42 days (red blood
cells) whilst plasma and cryoprecipitate may be stored at low tem-
perature for up to 1 year. This makes storage, inventory management
and distribution diﬀerent for each constituent and necessitates rigorous
track, trace and oversight procedures. Just as for CGTs the eﬃcacy of
blood transfusions can decrease with shelf life. Shelf life, scheduling
and the preservation of eﬃcacy is one of the biggest challenge for ef-
fective inventory management for CGTs. Demand-led distribution is
easier for blood products because they are lower value and easier to
store. Maintaining local inventory is more cost eﬀective. For CGTs, the
products are highly specialised, diﬃcult and costly to store and trans-
port and require a specialist environment for receipt of goods. This in
turn increases the risk of logistical breakdowns. The ﬁnancial implica-
tions of wasted blood products are costly at around £120 per unit of
blood to over £1000 for some products (NHSBT, 2016). This cost is a
fraction of that from even one missed treatment of a CGT due to the
much higher costs involved.
Breaking the blood supply chain down into discrete echelons allows
examination of complex interactions. These include managing the risk
of substitution (or mismatching) of products, reﬁning inventory levels,
applying scheduling models, location-based decision making or trans-
hipping. Supply and demand aﬀect decision making in all echelons.
Modelling the process as a whole better represents the relationship
between supply and demand and how they are linked to all the inter-
mediate steps. Without this whole system perspective, it is challenging
to enact eﬀective policies. Integrated models for the blood supply chain
have been around for over 30 years (Page, 1980) and can be used to
evaluate strategic proposals to the overall distribution strategy.
The blood supply chain in its current form has evolved over the
years, driven by a requirement to cut costs, to maintain patient safety
and to correct some notable failures. The most well-known failures are
the historic tragedies with infectious pathogens the ﬁrst of which
manifested in the form of hepatitis B in the blood-transfused survivors
of World War Two. It took decades to positively identify a screening
solution through a chance ﬁnding by a geneticist in 1963 (Alter and
Klein, 2008). This tragic spread of infection through the live-saving
blood transfusion service was again repeated in 1981 as strange
symptoms began to be reported in isolated patient groups. This was of
course later identiﬁed as the human immunodeﬁciency virus (HIV)
(Centres for Disease Control and Prevention (CDC, 2006). These cases
of infection are strong reminders that rigorous screening processes must
be in place to identify and to prevent contamination of patient material.
This is particularly pertinent as endpoint pathogen reduction techni-
ques available to the blood supply services, such as UV exposure or
chemical cleansing (Alter and Klein, 2008), are not as yet suitable for
CGTs. Treatment of the blood supply chain more as a manufacturing
process and integration of operational management practices have been
instrumental in identifying and reducing failures (Blake, 2009) due to
less obvious causes. These include practices such as reducing wastage
by extending shelf lives of platelets and reducing shelf lives of ery-
throcytes as they may lose eﬃcacy (Williamson and Devine, 2013) over
time.
The current blood supply chain model could be used as a blueprint
for centralised manufacturing of CGTs. The high-speed, high volume
management of procurement and administration with full track and
trace, segregation of lots and accompanying QC which has evolved to
manage the blood supply chain could provide valuable insights to fu-
ture CGT supply chains. The collection of autologous material, pro-
cessing/expansion and subsequent supply closely mirrors the blood
service system. Similarly, expansion and supply of multiple haplo-
banked donor materials which are then used to treat large portions of
the patients with a matching proﬁle, are similar in many respects to the
current supply of typed blood products. Indeed, as a relatively mature
industry, the blood supply chain can utilise ﬁxed and variable, mobile
locations for acquisition and processing of blood products. As the CGT
ﬁeld similarly matures, mobile manufacturing centres may become a
possibility. These interesting parallels allow for exciting postulations on
the operation of future CGT businesses based on the operational ex-
periences developed with blood products yet they operate under very
diﬀerent regulatory frameworks and this limits the direct translation pf
practices.
The centralised model has limitations. For blood supply a level of
wastage is accepted in order to meet an unknown and variable demand.
For CGTs this aspect can only be exacerbated by the shorter shelf life of
many CGTs. The current reality is that blood products are derived from
multiple donations by a small percentage of the population. This is
Fig. 2. The major echelons of the blood supply chain compared and contrasted with a case study with characteristics typical of a centralised model for manufacturing cell and gene
therapy products.
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similar to some features of a centralised model and of a decentralised
model. Two key features of the blood supply paradigm are relevant to
CGT. Firstly, the entire process from source to supply should be con-
sidered and, secondly, the semi-personalised nature of blood products
must be matched to patient requirements.
2.5. The additive manufacturing paradigm
Additive manufacturing (AM) is the process of generating a three-
dimensional construct from a set of design speciﬁcations via the layer-
by-layer deposition of starting material. Advances in this ﬁeld have had
a profound impact on the manufacturing industry, enabling the de-
centralised production of small lot sizes of complex components, and
moving make-to-stock products to a make-to-order business model with
the accompanying inventory reduction and without the need for highly
specialised manufacturing equipment and skilled operators (Weller
et al., 2015).
Current applications for AM are widespread, with such technology
being adopted in the aerospace, automotive and biomedical industries
among others. Energy and emissions-saving potential of AM has also
been highlighted (Huang et al., 2016). In the biomedical industry, AM
is now a focus of many medical research projects as a potential method
for the fabrication of three-dimensional products and devices, allowing
custom-made patient-speciﬁc constructs to be produced at point of care.
These constructs range from relatively simple prosthetics or implants to
highly complex combination products containing cellular and scaﬀold
components. This is now commonly known as biofabrication (Pavlovich
et al., 2016).
The revolutionary potential of such technology is highlighted by the
recent successful facial reconstructive surgery of a patient involved in a
severe road traﬃc accident. Computer-aided design and AM were ap-
plied to every stage of the process, from planning to surgery. Computed
tomography scan data was used to generate a symmetrical three-di-
mensional model of the patient's skull, which enabled the design of ISO
13485-(Quality management systems for medical devices) accredited
surgical tools. Traditionally such tools and devices would be crudely
measured for production in the operating theatre with the risk of error
and sub-optimal surgery results, requiring further corrective operations
(Peel et al., 2016). Furthermore, 3D–printers have also become avail-
able to the mass consumer market. The lower prices appeal to designers
and oﬀer a reliable way to replace spare parts for appliances.
‘Black–box’ technologies such as 3D printers shift the development re-
quirements of the product manufacturer away from process design and
towards product design (Baumers et al., 2016; Huang et al., 2015).
Whilst there is great potential within the AM sector to revolutionise
the supply of customised goods, there remain barriers to its adoption.
These constraints stem both from the relative immaturity of the tech-
nology as well as the path towards successful commercialisation and
regulation of an additively manufactured healthcare product. The RiHN
feasibility study conducted examining this issue highlighted the tech-
nology immaturity as well as regulatory uncertainty (Hourd et al.,
2015) as key limiting factors for the commercial success of AM
(Kapletia, 2015).
For the decentralised manufacturing of the more complex scaﬀold-
based CGT products AM, when coupled with appropriate cell expansion
technologies, can be a key enabler if the regulatory challenges re-
garding customised combination products can be overcome. This
technology holds the potential to manufacture low-volume products
reproducibly at numerous sites. Time from manufacturing to theatre is
likely to be critical for this class of product. Thus, release of these
products should rely on a fast and preferably non-invasive testing
methodology for produced products (Hourd et al., 2015). Additionally,
the relationship between customer and manufacturer should as a
minimum be governed by an enhanced quality agreement and future
clinical manufacturing models may be able to operate as a joint ven-
ture.
3. Technical and social barriers to the advancement of
redistributed manufacturing
CGTs have potential to produce huge beneﬁts for societal health.
Even with the correct choice of manufacturing and distribution models,
challenges remain when navigating the diﬃcult technical and social
decisions which aﬀect translation.
3.1. Technical barriers
There are various technical barriers that must be overcome such as
poor understanding of the underlying biology and mechanism of action
as well as gaps in process monitoring, cell expansion and cell processing
technologies.
CGTs rely upon a wide range of mechanistic approaches involving
stem cells, immune cells, gene therapy, multi-cellular constructs and
bio-engineered scaﬀolds. Emerging cell therapies, and some on the
market, show a lot of therapeutic promise, yet is no single universal
functional or potency assay that can be relied upon adequately to
measure all the CQAs and to predict clinical eﬃcacy. Whilst potency
remains challenging to measure for certain cell types, progress is being
made particularly in the chimeric antigen receptor T-cells (CAR-T) ﬁeld
(Quintarelli et al., 2016). Despite these advancements, the recent
deaths during the clinical trial of Juno's CAR-T therapy highlight the
challenges in simplifying function to a limited assay panel
(DeFrancesco, 2017). The promising results in the CAR-T ﬁeld de-
monstrate simpliﬁcation of functionality to a handful of in vitro mea-
surements is ambitious but possible, and vital for realising hypothesis-
driven mechanism of action assays suitable for use across a decen-
tralised manufacturing network (Galipeau et al., 2016) (Bravery et al.,
2013).
Eﬀective collection and management of in-process data is key to the
success of decentralised manufacturing of CGT products. Through ef-
fective Manufacturing Execution System (MES) the pre-process, in-
process and release data can be leveraged to both apply controls to the
manufacturing process, but also examine the trends emerging from such
data and to tighten, when appropriate, controls across the other sites
and not just the one where the observations arise. Petabytes of data may
be collected and the management, archiving and re-interrogation of
such data must feature in the operational management plan with
transmission integrity validated for the distributed network.
With CGTs, there is the need to release product batches as close to
real time as possible due to inherent product instability. As CGTs are
live products, cannot be terminally sterilised and should thus be treated
as aseptic goods. Thus there will need to be a high level of conﬁdence in
the ability of the process to prevent entry of microorganisms and
minimise deviations from parameters. This may rely on development of
validated and automated procedures to demonstrate the level of con-
trol. For asepsis this could include media ﬁll studies as in protein
manufacture or a process step to measure the bioburden of the goods. In
cases where end-point characterisation cannot be eliminated com-
pletely, batch hold times could potentially be reduced and/or products
released ‘at risk’ pending further results by showing alignment with
past in-process data. For sterility data, referring back to the demon-
strable bioburden earlier in the process is simpler, for product char-
acteristics, this is more challenging, although emerging label free
monitoring methods based oﬀ physical characteristics may pave the
way for more informed release criteria (Vaillier et al., 2016).
Controlling variation across multiple sites is pivotal when designing
any CGT manufacturing process. Sources of variation arise in both au-
tologous and allogeneic based processes. The source of this variation
will primarily be derived from patient starting material for the former,
whilst the process itself is likely to be of primary concern for allogeneic
products with a constant starting material. For decentralised manu-
facturing process considerations become even more important as sig-
niﬁcant process variation between manufacturing sites cannot be
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tolerated.
It is currently challenging to reduce user-related variability during
upstream cell-expansion and downstream processing. This inherent
reliance on manual operations and their concomitant variability is one
of the greatest technical barriers to decentralised manufacturing. By
mapping the degree of variation that can be accommodated through
process manipulations within certain boundaries (e.g. expansion dura-
tion, content of cytokines), in-process control feedback loops can be
established to predicted scenarios. These changes can then be applied
until the desired outcome is achieved in a responsive manner. Whilst
desirable, this scenario potentially relies upon removing operator in-
terventions and replacing them with automated processes. This ‘adap-
tive automation’ remains largely aspirational currently with only
simple introduction or transference of materials possible with existing
production platforms.
Maintaining security of both the manufacturing process and the
supply chain feeding into it are essential for ensuring quality. Supply
chain management, from inputs to outputs, becomes increasingly
challenging when cooperation between partners is poor. A key value
proposition for an eﬀective re-distributed service of manufacture will
be the timely supply of goods and services without the customer having
to worry about it, yet it is particularly susceptible to fragmentation of
the chain of custody and good communication and alliance manage-
ment must be applied to avoid this. Checks must be in place to mitigate
deviation from the manufacturing speciﬁcation and subsequently to
avoid product variation from site to site. Examples of systems which
facilitate the integrity of this supply chain already exist both in the
consumer space with the range of smart appliances, and in the com-
mercial life-sciences and healthcare sector with OptiMed-ID and
ThermoFisher Smart Monitoring systems some of the leading examples.
These smart systems are driven by the increasing ubiquity of smart
computer-like devices and a network of these devices are likely the
solution for maintaining integrity of the decentralised network.
3.2. Social barriers
Perhaps more challenging than the technical requirements are the
radical changes needed for wider societal acceptance of decentralisa-
tion of manufacturing. These include not only a substantial change in
the organisation of labour and roles for human operators, but also a
shift of the burden of responsibility as operators are removed from the
process and replaced with automated solutions.
Realisation of the potential of decentralised manufacture will re-
quire automated solutions to many of the process steps, but will not
remove the necessity for a highly-motivated and skilled workforce.
Similarly, it has been highlighted that there is an apparent skills gap in
the sector (Medicine Manufacturers Industry Partnership, 2016) and as
the ﬁeld progresses, there may be the necessity to have a new specialist
training regimen to supply the growing demand for skilled labour.
Traditional centralised manufacturing concentrates labour and, in turn,
creates a pool of collective expertise. The success of decentralised
manufacturing relies upon portioning out the workforce into tranches
of skilled operators. One of the key weaknesses of decentralised man-
ufacturing is the threat of a poor skills pool and ageing workforce in a
localised economy (Shucksmith and Brown, 2016) and this must be
taken into account. Successful relocation of labour could involve
‘technology transfer champions’ from the current rising researcher base
who are young, mobile and keen to make a diﬀerence at the interface
between manufacturing and practice of translational medicine. Ad-
ditionally, due to the dispersed operational nature of the workforce
eﬀective personnel management utilising licensed remote site opera-
tions, mandatory re-training and centrally managed control standards
blinded to the remote facilities to check performance.
It is traditional to regard many aspects of manufacturing and quality
control as proprietary knowledge. While interoperability of manu-
facturing equipment has been successful for some consumer product
manufacturing it is still lacking in many sectors where the goods are
specialised. Achieving technology platforms for manufacturing CGTs
involving equipment from multiple manufacturers will require not only
technical expertise but a willingness to share pre-competitive in-
formation.
The roles and responsibilities of the agents in a decentralised
manufacturing network require careful deﬁnition. CGT product devel-
opment is largely pursued by academia, hospitals and small to medium
sized enterprises (SMEs) which typically do not have the resources
available to big pharmaceutical companies (Celis and Salmikangas,
2011). Recently, there have been a number of high proﬁle cases of
funding, mergers and acquisitions in the sector (American Association
for Cancer Research, 2017) which highlight the value present in the
industry (Caplan et al., 2017).
it is highly likely that decentralised manufacturing processes will
involve multiple stakeholders in terms of the equipment and expertise
that is needed. In decentralised manufacturing, some of these stake-
holders might also share commercial rights to the process, technology
or product. Due to the high set-up costs of any infrastructure, it is
preferable that any manufacturing platform should be used to create
multiple product types for multiple stakeholders in order to spread the
ﬁxed costs of operation. In doing so, the stakeholders might share the
responsibility for reliable manufacturing and enjoy a portion of the
associated revenue while spreading the capital investment by ‘sweating
the assets’. Achieving this shared decentralised facility model is chal-
lenging, particularly with the diverse range of CGT products available.
However, by creating a typology of manufactured CGTs which groups
products by common unit operations, standardised production lines
may be able to be established. As the ﬁeld matures, new production
lines may be established which cater for particularly lucrative products
within emerging typologies.
To understand the extent of the socio-economic beneﬁts that de-
centralised manufacturing could yield, it is important to understand
where real value can be created. In this case, value can be described as
the stored investment in terms of the proportion of selling price build
up in the work in progress plus inventory at any one time. Locating
most of the production and servicing activity close to the end user has
the highest potential to capture value (Moreno and Charnley, 2016).
This could be through a multitude of avenues of which reduction in loss
of manufactured batches has proven to be signiﬁcant in the case of
MySkin (Hernon et al., 2006), Advanced Tissue Sciences and for
pharmaceutical clients of eXmoor Pharma (Personal Communication,
Nicholas Medcalf). This is a radical model and, as such, re-imbursement
will present challenges because of the dispersed ownership of the chain
of custody.
3.3. Perspectives
Over the last 20 years, the CGT industry has been rapidly advancing
and real patient beneﬁts from these approaches are being witnessed.
Whilst signiﬁcant progress has already been made, the relative infancy
of this ﬁeld still demonstrates a potential for major growth (Mason
et al., 2013). This is made evident not only by the large number of
clinical trials and by the over 800 companies focussed on CGTs
(Alliance for Regenerative Medicine, 2017). This is reinforced by the
forecast of the UK government who expect a number of CGTs to be
available within ﬁve years (Science and Technology Committee, 2013).
3.4. Decentralised manufacturing progress: A case study of the UK
The UK is a key exemplar for the progress of CGT manufacturing.
The high level of the skills base and strong support by central govern-
ment make it an attractive place for innovation. The recent vote for the
UK to leave the European Union, whilst disruptive to normal operating
practices, has precipitated a ﬂurry of dialogue about how the UK can
beneﬁt from new technologies, making it an interesting case in point for
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feasibility-testing decentralised manufacturing.
A number of the themes presented in this article align strongly with
recent recommendations from the UK Medicine Manufacturing Industry
Partnership report: ‘Advanced Therapies Manufacturing Action Plan’
(MMIP, 2016). This plan advocates a strategy to capture investment,
secure manufacturing capability and talented labour in the UK and
embrace novel social and regulatory mechanisms to grow the CGT
business community in the UK. Many of these action points focus on
capturing and concentrating funding, technology, assets and people. We
would argue that concentrating these into small decentralised facilities
operating to a common quality management system (QMS), has the
potential to add greater value to the UK as a whole than a centralised
model. Additionally, this model will, by design, add resiliency to the
network of provision of healthcare products as manufacturing platforms
can accommodate for capacity shortfalls in the event of increased de-
mand or in the event one facility is oﬄine due to disaster.
The report identiﬁes a talent management plan but places no em-
phasis on geographical demands for labour, which we believe is of
critical importance for regional investment strategy. The topic of
standards and regulation was recognised as a key stumbling block and
the authors recommended early engagement with the regulator. We
fully agree with this view and would argue that emphasis should also be
placed on establishing guidelines for responsibility and liability be-
tween stakeholders involved in the product chain of custody. A large
proportion of this would be covered in supply agreements between
organisations, however a breakdown in the chain of custody can occur
because of poor practice right up to the point of application and there
needs to be an incentive to cooperate in maintaining asepsis at least.
Our view that automation of processes is critical to achieve process
comparability while lowering the cost of goods is supported by the
ﬁndings of the report. We have argued that the additional beneﬁts af-
forded by automating processes allows for a decentralised model with
manufacturing situated closer to patients and this is supported by the
report. We have argued that manufacturing of some CGTs such as CAR-
T cell therapies is best served by a decentralised manufacturing model
(Yin, 2017). One of the most relevant proposals in the report is the
establishment of CGT treatment centres. The aim of these would be to
support the provision of CGTs by providing the infrastructure required
to deliver advanced therapies.
The report recognises the powerful addition of the large scale
manufacturing centre for the Cell & Gene Therapy Catapult that comes
on stream in 2018. Decentralisation will remain a very attractive option
for manufacture and delivery of CGT products in situations that demand
a high degree of personalisation, where fresh delivery is desirable and
where there is high value release from a low volume of products. Such
an arrangement could be provided by an extension of the model de-
scribed by Porter and Teisberg (Porter and Teisberg, 2006), in which
specialised administration of CGT products is accompanied by specialist
manufacturing in a clinical production unit.
3.5. Summary ﬁndings and vision
As the CGT ﬁeld develops, it becomes evident that the strength of
many products comes from personalisation for speciﬁc uses. This per-
sonalised approach oﬀers enormous possibilities for patients but ne-
cessitates alternative manufacturing models.
A centralised model for CGT manufacturing is much closer in design
to existing manufacturing infrastructures where economies of scale
could be realised. A theoretical ﬂow diagram for a centralised manu-
facturing model is presented in Fig. 3. In a centralised model, a large
number of products are delivered to a central location where they are
completed and a ﬁnished product is supplied to the end user. This
manufacturing model, whilst familiar, is likely to incur disadvantages
from its distance from the user, geographically and in terms of re-
sponsiveness to end-user requirements. Logistical management may
result in product wastage as the longer the supply chain, the more
opportunity for error and mis-timing of delivery.
By situating manufacturing closer to the end consumers, it is hoped
these shortcomings can be overcome and additional beneﬁts can be
gained in the formation of enduring, eﬀective alliance management. A
theoretical framework which draws on the paradigms described in this
paper is presented in Fig. 4. This assumes that research and develop-
ment will be carried out oﬀ-site to generate standards and to ensure
comparability across sites. The manufacturing process for the ‘Drug
Product’ itself is assumed to be located adjacent to the clinical facility
and that appropriate transit trials would be conducted for the transit
points described in the ﬁgure (Harrison et al., 2017b).
In these process diagrams, three key areas (Fig. 5) are identiﬁed as
pivot points which support decentralisation of the manufacturing pro-
cess. The ﬁrst and most obvious consideration is the starting material.
Banked materials located in a central facility are much easier to in-
corporate into a centralised manufacturing process. If materials are to
be collected fresh from a patient, situating a manufacturing centre close
to the collection point signiﬁcantly simpliﬁes collection logistics. The
second consideration is transport which can have a signiﬁcant impact
on the underlying biology of CGTs and thus shipping and stability must
be suitably qualiﬁed. In addition to this, fresh transport can be very
costly as it requires active management of the product which is eﬀec-
tively still in culture. Packaging containers and chemically based en-
vironmental management products such as the Sanplatec Culture Pal®
have been developed to aid in fresh shipping but if time is a critical
factor in product shelf-life then costs can quickly mount up for dedi-
cated transport over anything other than short distances. In cryopre-
served products the maximum transit duration increases which allows
pooling of deliveries and thus freight costs drop (Personal Commu-
nication, Steve Langron, Lime Associates). Consequently a number of
companies are developing cryogenic distribution strategies including
ThermoFisher, Trust Express, CryoSend Mitsui Soko Holdings, Cryoport
and Medipal Holdings (Sampson, 2017). Currently this does limit the
number of clinics able to receive a cryopreserved product due to the
rarity of low temperature goods inwards facilities and suitable thawing
areas.
Another barrier for large scale manufacture of CGTs is the high cost
of wet consumables such as culture medium. Manufacturing to order as
closely as possible is essential to minimise wastage. Location decisions
for blood centres, for example have to be strategic and decision-making
models for calculating supply and demand taking into account proxi-
mity and perishability already exist. These principles could be utilised
for CGT products to determine serviceable locations for diﬀering pro-
duct categories from each manufacturing facility.
Of the exemplars chosen, blood and blood products such as bone
marrow transplants, represents in our view the best basis for decision
making about processes. This is due not only to the similarities of the
product type, but also the similarities of the whole process. The blood
supply chain can be examined as a whole unit, from sourcing to end
user, making it distinct from other industries which are rather a subset
of a larger manufacturing ecosystem (Pierskalla, 2005). The blood
manufacturing supply chain in its current form is a relatively mature
area. However, it has not overcome the natural variation in supply and
demand and is constantly optimising in response to supply challenges.
The maturity of the ﬁeld and the paramount requirement for reducing
both cost and wastage has yielded a number of detailed models which
have increased in complexity over the last thirty years (Beliën and
Forcé, 2012). These models capture best practices that result from ex-
perience and provide the groundwork for developing similar models to
guide a CGT manufacturing supply chain and avoid product wastage
due to oversupply, errors or failed delivery (Hernon et al., 2006).
4. Concluding remarks
Centralised manufacturing is highly suited for products where the
product life-cycle and shelf life are long, where the unit operations are
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Fig. 3. Model process diagram for centralised manufacturing of cell and gene therapy products. Starting materials can originate at a clinical facility for an autologous product (1) or from
the master cell bank for an allogeneic product (3). Product manufacturing steps which are likely to contain a signiﬁcant analytical monitoring component are linked with the grey process
lines. Alternative process steps are signiﬁed by dotted and dashed lines. The thaw and formulate step alternative is an example of a process where the Drug Substance is managed as a hold
step before formulation to give the Drug Product.
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well-established and where the degree of personalisation is low. The
increasing need for personalisation of CGT products is best addressed
by low-volume, multiple manufacturing lines at least for the ﬁnishing
unit operations. Such a system is diﬃcult to implement in a centralised
operation while maintaining capacity. This makes the entire process a
trade-oﬀ between degrees of personalisation and throughput. Examples
of these personalised products might include engineered tissues other
than hyaline cartilage and epidermis as well as bio-printed constructs.
Decentralised manufacture is similar to the cottage industries of old
located close to end users and responsive to their needs. In order for
decentralised manufacturing of complex healthcare products to
succeed, it must address the key weakness that distance always pre-
sents, namely product consistency, not just from the process, but also
from unanticipated risk factors such as accidents, human error, trans-
port delays and failures and natural disasters. The industry cannot
permit signiﬁcant local variation in quality. Each site must demonstrate
its ability to deliver an equivalent product regardless of location or
operators. This is best assured by judicious use of automated systems.
By removing human operators from key stages this problem should be
ameliorated, presenting a responsive process without the drawbacks of
variability. Managing this inherently complex network of manu-
facturing hubs requires integrated management systems. Automated
Fig. 4. Model process diagram for decentralised (redistributed) manufacturing of cell and gene therapy products. Starting materials can originate at a clinical facility for an autologous
product (1), which may be transferred to the central facility (3) as part of the manufacturing process. Alternatively, a master bank containing an allogeneic product may be shipped out to
decentralised manufacturing facilities from a central facility. This movement of material to and from the central facility may involve the creation of a mater bank or it may be created at
the decentralised facility (4). Product manufacturing steps which are likely to contain a signiﬁcant analytical monitoring component are linked with the grey process lines. Alternative
process steps are signiﬁed by dotted and dashed lines.
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systems promise to deliver both integrated management and com-
pliance but signiﬁcant challenges remain over implementation and
regulatory acceptance.
In addition to the signiﬁcant challenges associated with capacity
and consistency, questions remain over eﬀective reimbursement of
these expensive products. The lessons from Sovaldi are clear, alter-
native reimbursement strategies are key to commercial success. In the
paradigms presented here, high point-of-sale costs for radioisotopes
may justify the high sunk costs of acquiring the manufacturing unit.
This same strategy could be implemented for decentralised manu-
facture of CGTs.
Decentralisation of manufacture of CGT products is an attractive
proposition for high-value, low volume goods that require personali-
sation. Suitable automation platforms need not reduce the need for
human operators but they may change their role, creating a new layer
of semi-skilled operators through the externalisation of some of the
know-how to the machines themselves. The interdependence of such
centres in a ‘hub-and-node’ network has the potential to make manu-
facturing resilient and largely immune to disasters and to demand
ﬂuctuations. A network of customer clinics, such as exists in the UK in
the form of the National Health Service (NHS), oﬀers the opportunity to
create boilerplate training and quality management systems and fra-
mework agreements to facilitate roll-out and relationship management,
between the manufacturer and the NHS. The social experiment of the
Fig. 5. Key decisions which inﬂuence the decision to de-
centralise manufacturing. Ease of sourcing of starting ma-
terials can be inﬂuenced by both on-site expertise and local
collection capacity (1). Distance from the manufacturing
centre to the patient or clinic can dictate what transport
options are available for speciﬁc CGT product classes at a
given operational size (2). Diﬀering CGT product classes
may have challenging logistical requirements (3).
Centralised and decentralised facilities have diﬀering la-
bour requirements with the latter risking production if the
skilled labour pool is weak. Managing talent across national
boundaries may be challenging to administer (4).
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roll-out, the re-examination of reimbursement arrangements and the
technical challenge of comparability in manufacture can be seen as the
price that needs to be paid for an agile, environmentally friendly, re-
sponsive way of delivering advanced treatments. Indeed, the huma-
nising inﬂuence of networks of such enterprise and their inter-
dependence can be seen as an example of Schumacher's famous
principle that “small is beautiful”.
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